CVM-1118
Phase 2Small molecule
CVM-1118 is one of 26 small molecule programs targeting Hepatocellular Carcinoma. It is currently in Phase 2.
1
Indications
4
Total Trials
2
Active Trials
25
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
797 competitors in Hepatocellular Carcinoma
#DrugCompanyPhaseTrials
1Ibrance
PfizerPreclinical
Viread
GileadPreclinical
Sovaldi
GileadPreclinical
Coreg
Akero TherapeuticsPreclinical
Vermox
WWim Janssens
Preclinical
Opdivo
Bristol-Myers SquibbPreclinical
CVM-1118
TTaiRx, Inc.
Phase 2
Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Statin
Bristol-Myers SquibbPreclinical
Anlotinib
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Hepatocellular Carcinoma2 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CVM-1118. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- TTaiRx, Inc.